アジア太平洋地域の腎臓がん診断市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2024 –2030 |
 市場規模（基準年） |
|
 Market Size (Forecast Year) |
USD 3,240.00 |
 CAGR |
% |
| 主要市場プレーヤー |
アジア太平洋地域の腎臓がん診断市場、検査タイプ別（イメージング、バイオマーカー検査、血液検査、生検、遺伝子検査など）、がんのステージ別（ステージI、ステージII、ステージIII、ステージIV）、腫瘍タイプ別（腎細胞がん、明細胞腎細胞がん、非明細胞腎細胞がん）、製品別（プラットフォームベースの製品、機器ベースの製品、キットおよび試薬、その他の消耗品）、技術別（蛍光in situハイブリダイゼーション、次世代シーケンシング、蛍光免疫測定法、比較ゲノムハイブリダイゼーション、免疫組織化学、その他）、用途別（スクリーニング、診断および予測、予後、研究）、エンドユーザー別（病院、診断センター、がん研究センター、学術機関、外来手術センター、その他）、流通チャネル別（直接入札、小売販売、その他）、業界動向および2030年までの予測。
アジア太平洋地域の腎臓がん診断市場の分析と規模
腎臓がんは、片方または両方の腎臓の健康な細胞が変化し、制御不能に増殖して皮質腫瘍と呼ばれる塊を形成することで始まります。腫瘍は悪性、無症状、良性の場合があります。悪性腫瘍は癌であり、増殖して体の他の部位に転移する可能性があります。無症状腫瘍も癌ですが、このタイプの腫瘍が体の他の部位に転移することはほとんどありません。良性腫瘍は、腫瘍が増殖することはあっても転移しないことを意味します。
アジア太平洋地域で腎臓がんに対する意識が高まったことで、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に寄与しています。主要な市場プレーヤーは、この重要な時期にさまざまなサービスの立ち上げと承認に注力しています。さらに、腎臓がんの診断手順の改善の増加も、腎臓がんの診断検査の需要増加に寄与しています。
アジア太平洋地域の腎臓がん診断市場は、市場プレーヤーの増加と高度なサービスの利用可能性により、予測年度に成長すると予想されています。これに伴い、メーカーは市場に新しいサービスを立ち上げるための研究開発活動に取り組んでいます。腎臓診断と開発の分野での研究の増加により、市場の成長がさらに促進されると予想されます。ただし、画像検査による高放射線被曝による組織損傷は、予測期間中のアジア太平洋地域の腎臓がん診断市場の成長を妨げると予想されます。
Data Bridge Market Research の分析によると、腎臓がん診断市場は予測期間中に 6.9% の CAGR で成長し、2030 年までに 32 億 4,000 万米ドルに達する見込みです。スマート デバイスの需要が高まっているため、イメージングが市場で最大のテスト タイプ セグメントを占めており、医療費の増加によりスマート医療デバイスの需要が加速しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (Customizable to 2020-2016) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stage (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Non Clear Cell Renal Cell Carcinoma), Product (Platform Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others). |
|
Countries Covered |
China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the rest of Asia-Pacific. |
|
Market Players Covered |
Siemens Healthcare GmbH, Koninklijke Philips N.V., FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene N.V., GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D, and CD Genomics, and BD, among others |
Market Definition
Kidney cancer, commonly known as renal cancer, is a condition in which kidney cells develop into malignant (cancerous) tumors and expand uncontrollably. One of the top 10 most prevalent cancers is kidney cancer. Kidney cancer is fatal, and the diagnosis process also has safety issues; it is not cost-effective. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. About 40% of kidney growths are tiny, localized masses. Localized refers to a tumor that has not spread from its original location. Kidney masses cannot be detected with regular laboratory procedures. Diagnosis of kidney cancer includes biopsy procedures, blood tests, and Imaging tests. Advanced kidney cancer therapies, like immunotherapy, radiation therapy, etc., are advised. Due to cutting-edge methods, nonsurgical procedures like cryoablation (which freezes cancer cells) and radiofrequency ablation are sometimes used to treat minor kidney tumors (heat cancer cells).
Kidney cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. More than 43,000 men and 25,000 women are diagnosed with kidney and renal pelvis cancer each year, and 9,000 men and 5,000 women pass away as a result of this illness. However, strict regulations and standards for the approval and commercialization of kidney cancer diagnostic products are expected to restrain market growth.
Asia-Pacific Kidney Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Prevalence of Kidney Cancer
All ages can be affected by this type of cancer. Kidney cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Kidney cancer usually has no signs or symptoms in its early stages. Over time, signs and symptoms may occur, including blood in the urine, which may appear pink, red, or cola-colored, back or side pain that does not go away, loss of appetite, unexplained weight loss, fatigue, and fever. In adults, kidney cancer is the most common type of cancer. Young children are more likely to develop a type of kidney cancer called Wilms tumor. Renal cancer (also known as kidney cancer or renal cell adenocarcinoma) is the 14th most common cancer worldwide. It is 9th among men and 14th among women. In 2020, more than 30,000 new cases of kidney cancer were diagnosed.
Due to various risk factors such as smoking, obesity, high blood pressure (hypertension) or family history of kidney cancer, patients with kidney cancer is rising Asia-Pacific and becoming a significant socio-economic issue. Thus the rising number of patients with kidney cancer increases the demand for kidney cancer diagnostics products which act as a driver in the Asia-Pacific kidney cancer diagnostics market.
- Increase in Diagnostic Procedures for Kidney Cancer
Techniques used to diagnose kidney cancer include ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) and, sometimes, positron emission tomography (PET) scans. Treatment for kidney cancer with a slow growth rate may involve monitoring. Chemotherapy for malignant is occasionally combined with radiation therapy and stem cell transplant. The increasing cancer rates have been a boosting factor for the increasing diagnostic product approval.
Thus, the rise in diagnostic product approvals has led to an increased number of highly efficient products in the market for kidney cancer diagnosis treatment. This is expected to act as a driver for the growth of the Asia-Pacific kidney cancer diagnostics market.
Opportunity
-
Rising Preference for Preventive Health Check-Ups
Preventive health check-up is preventive actions performed for the initial detection of kidney cancer disease. Also, a rising preference for preventive health check-ups provides a safeguard against likely exposure to any disease in the future.
Awareness to promote screening is the most important component of kidney cancer prevention. The check-up is comprised of the identification of cancer and examinations of risk factors to limit loss at an early stage.
Preventive kidney cancer check-up is performed with the help of various diagnostic test, which includes biopsy, immunohistochemistry, cancer screening, MRI and among others.
People are relatively more prone to kidney cancer diseases. Therefore, they require going through regular check-ups to facilitate physicians develop an understanding of diseases and to provide better treatment to a patient who is suffering from cancer, for the reason rising preference for preventive health check-ups is expected to act as a driver for the growth of Asia-Pacific kidney cancer diagnostics market.
Restraint/Challenge
- Strict Regulations And Standards For The Approval And Commercialization Of Kidney Cancer Diagnostic Products
The stringent regulations for the commercialization of any product in the market are proving to be a big challenge for the manufacturers of cancer diagnostic products Asia-Pacific that have regulations and a different body for the regulatory procedures.
Manufacturers first have to check the CE mark approval for their product's commercialization into the Asia-Pacific market. The stringent regulatory policies are expected to hinder the development of the cancer diagnostic market. The regulatory requirement for approvals of marketing or CE certification and application of laws and regulations could lead to major business changes or paying penalties, including the potential loss of business licenses. The resources and costs required to comply with these laws, rules, and regulations are high.
The regulatory requirement for marketing approvals, declaration of conformity, and the time required for regulatory review may vary for different products. The company which fails to get regulatory approval harms the business because without getting approval or failing to get CE to mark approval on the products, manufacturers are not able to launch their product in the Asia-Pacific market, and for this reason, strict regulations and standards for the approval and commercialization of kidney cancer diagnostic products are expected to act as a restrain for the Asia-Pacific kidney cancer diagnostics market.
Recent Developments
- In November 2022, Koninklijke Philips N.V. announced the Asia-Pacific launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is Compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped the company to expand its product portfolio.
- In October 2022, General Electric Company had collaborated with several research institutes like the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics.
- In July 2022, Canon Medical Systems USA Inc. announced the completion of the acquisition of NXC Imaging, a medical imaging equipment distributor and service provider located in Minnesota, U.S. This results in expanding the service outreach in the Asia-Pacific market.
Asia-Pacific Kidney Cancer Diagnostics Market Scope
The Asia-Pacific kidney cancer diagnostics market is segmented into eight notable segments based on test type, cancer stage, tumor type, product, application, technology, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Test Type
- IMAGING TEST
- BIOMARKER TEST
- BLOOD TEST
- BIOPSY
- GENETIC TEST
- OTHERS
On the basis of test type, the Asia-Pacific kidney cancer diagnostics market is segmented into imaging, biomarker test, blood test, biopsy, genetic tests, and others.
Cancer Stage
- STAGE I
- STAGE II
- STAGE III
- STAGE IV
On the basis of cancer stage, the Asia-Pacific kidney cancer diagnostics market is segmented into stage I, stage II, stage III and stage IV.
Tumor Type
- RENAL CELL CARCINOMA
- CLEAR CELL RENAL CELL CARCINOMA
- NON-CLEAR CELL RENAL CELL CARCINOMA
On the basis of tumor type, the Asia-Pacific kidney cancer diagnostics market is segmented into renal cell carcinoma, Clear cell renal cell carcinoma, and non-clear cell renal cell carcinoma.
Product
- PLATFORM BASED PRODUCTS
- INSTRUMENT BASED PRODUCTS
- KITS AND REAGENTS
- OTHER CONSUMABLES
On the basis of product, the Asia-Pacific kidney cancer diagnostics market is segmented into instrument-based products, platform-based products, kits and reagents, and other consumables.
Technology
- FLUORESCENT IN SITU HYBRIDIZATION
- NEXT GENERATION SEQUENCING
- FLUOROIMMUNOASSAY
- COMPARATIVE GENOMIC HYBRIDIZATION
- IMMUNOHISTOCHEMICAL
- OTHERS
On the basis of technology, the Asia-Pacific kidney cancer diagnostics market is segmented into fluorescent in situ hybridization, next-generation sequencing, fluorimmunoassay, comparative genomic hybridization, immunohistochemical, and others.
Application
- SCREENING
- DIAGNOSTIC AND PREDICTIVE
- PROGNOSTIC
- RESEARCH
On the basis of application, the Asia-Pacific kidney cancer diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research.
End User
- HOSPITALS
- CANCER RESEARCH CENTERS
- ACADEMIC INSTITUTES
- DIAGNOSTIC CENTERS
- AMBULATORY SURGICAL CENTERS
- OTHERS
On the basis of end users, the Asia-Pacific kidney cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others.
Distribution Channel
- DIRECT TENDERS
- RETAIL SALES
- OTHERS
On the basis of distribution channel, the Asia-Pacific kidney cancer diagnostics market is segmented into direct tender, retail sales and others.
Asia-Pacific Kidney Cancer Diagnostics Market Regional Analysis/Insights
The Asia-Pacific kidney cancer diagnostics market is analyzed and market size information is provided based on country, test type, cancer stage, tumor type, product, application, technology, end user and distribution channel.
The countries covered in this market report are China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the rest of Asia-Pacific.
China dominates the Asia-Pacific region due to rising awareness of regular health checkups.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Kidney Cancer Diagnostics Market Share Analysis
The kidney cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the kidney cancer diagnostics market.
この市場で活動している主要企業としては、Siemens Healthcare GmbH、Koninklijke Philips NV、富士フイルム株式会社、Grail、Laboratory Corporation of America Holdings、Thermo Fisher Scientific、Myriad Genetics、Inc.、CANON MEDICAL SYSTEMS CORPORATION、QIAGEN、Illumina Inc.、Ambry Genetics、Invitae Corporation、General Electric Company、Centogene NV、GenPath、Creative Diagnostics、GeneDx LLC、Blueprint Genetics Oy、BioVendor R&D、CD Genomics、BDなどが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES
5 INDUSTRY INSIGHTS
6 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER
7.2 RESTRAINTS
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS
7.3 OPPORTUNITIES
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
7.4 CHALLENGES
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS
8 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING
8.2.1 COMPUTED TOMOGRAPHY
8.2.2 ULTRASOUND
8.2.3 MAGNETIC RESONANCE IMAGING (MRI)
8.2.4 ANGIOGRAPHY
8.2.5 X-RAY
8.2.6 OTHERS
8.3 BLOOD TEST
8.4 BIOPSY
8.4.1 FINE NEEDLE ASPIRATION
8.4.2 NEEDLE CORE BIOPSY
8.5 BIOMARKER TEST
8.5.1 AQUAPORIN 1 (AQP1)
8.5.2 PERILIPIN (PLIN2)
8.5.3 N-METHYLTRANSFERASE (NMNT)
8.5.4 L-PLASTIN (LCP-1)
8.5.5 NM23A
8.6 GENETIC TEST
8.7 OTHERS
9 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE
9.1 OVERVIEW
9.2 STAGE I
9.3 STAGE II
9.4 STAGE III
9.5 STAGE IV
10 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE
10.1 OVERVIEW
10.2 RENAL CELL CARCINOMA
10.2.1 IMAGING
10.2.2 BLOOD TEST
10.2.3 BIOPSY
10.2.4 BIOMARKER TEST
10.2.5 GENETIC TEST
10.2.6 OTHERS
10.3 CLEAR CELL RENAL CELL CARCINOMA
10.3.1 IMAGING
10.3.2 BLOOD TEST
10.3.3 BIOPSY
10.3.4 BIOMARKER TEST
10.3.5 GENETIC TEST
10.3.6 OTHERS
10.4 NON CLEAR CELL RENAL CELL CARCINOMA
10.4.1 PAPILLARY RENAL CELL CARCINOMA
10.4.1.1 IMAGING
10.4.1.2 BLOOD TEST
10.4.1.3 BIOPSY
10.4.1.4 BIOMARKER TEST
10.4.1.5 GENETIC TEST
10.4.1.6 OTHERS
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA
10.4.2.1 IMAGING
10.4.2.2 BLOOD TEST
10.4.2.3 BIOPSY
10.4.2.4 BIOMARKER TEST
10.4.2.5 GENETIC TEST
10.4.2.6 OTHERS
11 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 INSTRUMENT BASED PRODUCTS
11.2.1 IMAGING
11.2.2 BIOPSY
11.3 PLATFORM BASED PRODUCTS
11.3.1 NEXT GENERATION SEQUENCING
11.3.2 MICROARRAYS
11.3.3 PCR
11.3.4 OTHERS
11.4 KITS AND REAGENTS
11.4.1 RENAL CANCER PANELS
11.4.2 RENAL CANCER ANTIBODIES
11.5 OTHER CONSUMABLES
12 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
12.1 OVERVIEW
12.2 FLUORESCENT IN SITU HYBRIDIZATION
12.3 NEXT GENERATION SEQUENCING
12.4 FLUORIMMUNOASSAY
12.5 COMPARATIVE GENOMIC HYBRIDIZATION
12.6 IMMUNOHISTOCHEMICAL
12.7 OTHERS
13 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 SCREENING
13.2.1 INSTRUMENT BASED PRODUCTS
13.2.2 PLATFORM BASED PRODUCTS
13.2.3 KITS AND REAGENTS
13.2.4 OTHER CONSUMABLES
13.3 DIAGNOSTIC AND PREDICTIVE
13.3.1 INSTRUMENT BASED PRODUCTS
13.3.2 PLATFORM BASED PRODUCTS
13.3.3 KITS AND REAGENTS
13.3.4 OTHER CONSUMABLES
13.4 PROGNOSTIC
13.4.1 INSTRUMENT BASED PRODUCTS
13.4.2 PLATFORM BASED PRODUCTS
13.4.3 KITS AND REAGENTS
13.4.4 OTHER CONSUMABLES
13.5 RESEARCH
13.5.1 INSTRUMENT BASED PRODUCTS
13.5.2 PLATFORM BASED PRODUCTS
13.5.3 KITS AND REAGENTS
13.5.4 OTHER CONSUMABLES
14 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC CENTERS
14.4 CANCER RESEARCH CENTERS
14.5 ACADEMIC INSTITUTES
14.6 AMBULATORY SURGICAL CENTERS
14.7 OTHERS
15 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.4 OTHERS
16 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 CHINA
16.1.2 JAPAN
16.1.3 INDIA
16.1.4 SOUTH KOREA
16.1.5 AUSTRALIA
16.1.6 TAIWAN
16.1.7 NEW ZEALAND
16.1.8 INDONESIA
16.1.9 THAILAND
16.1.10 PHILIPPINES
16.1.11 MALAYSIA
16.1.12 VIETNAM
16.1.13 SINGAPORE
16.1.14 REST OF ASIA PACIFIC
17 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 CANON MEDICAL SYSTEMS CORPORATION
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY PROFILE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 KONINKLIJKE PHILIPS N.V.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY PROFILE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 GENERAL ELECTRIC COMPANY
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY PROFILE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 SIEMENS HEALTHCARE GMBH
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY PROFILE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 GRAIL
19.5.1 COMPANY SNAPSHOT
19.5.2 PRODUCT PORTFOLIO
19.5.3 RECENT DEVELOPMENTS
19.6 AMBRY GENETICS
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BIOVENDOR R&D
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BLUEPRINT GENETICS OY.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 CD GENOMICS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CENTOGENE N.V.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 CREATIVE DIAGNOSTICS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 FUJIFILM CORPORATION
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 GENEDX, LLC
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 ILLUMINA, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 INVITAE CORPORATION
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 MYRIAD GENETICS, INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 THERMO FISHER SCIENTIFIC INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.2 QIAGEN
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表のリスト
TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS
TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER
TABLE 3 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 ASIA PACIFIC IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA PACIFIC BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA PACIFIC GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 14 ASIA PACIFIC STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 31 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 32 ASIA PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 ASIA PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 35 ASIA PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 36 ASIA PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 ASIA PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 ASIA PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 39 ASIA PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 ASIA PACIFIC OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 42 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 ASIA PACIFIC NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 ASIA PACIFIC FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 ASIA PACIFIC COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 ASIA PACIFIC IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 ASIA PACIFIC OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 49 ASIA PACIFIC SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 ASIA PACIFIC SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 51 ASIA PACIFIC DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 ASIA PACIFIC DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 53 ASIA PACIFIC PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 ASIA PACIFIC PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 55 ASIA PACIFIC RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 ASIA PACIFIC RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 57 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 58 ASIA PACIFIC HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 ASIA PACIFIC DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 ASIA PACIFIC CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 ASIA PACIFIC ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 62 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 ASIA PACIFIC OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 65 ASIA PACIFIC DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 ASIA PACIFIC RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 67 ASIA PACIFIC OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 69 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 ASIA-PACIFIC IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 ASIA-PACIFIC BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 74 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 75 ASIA-PACIFIC RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 ASIA-PACIFIC CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 ASIA-PACIFIC NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 78 ASIA-PACIFIC PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 ASIA-PACIFIC CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 83 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 84 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 87 ASIA-PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 ASIA-PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 89 ASIA-PACIFIC KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 90 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 91 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 ASIA-PACIFIC SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 ASIA-PACIFIC DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 ASIA-PACIFIC PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 ASIA-PACIFIC RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 96 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 CHINA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 CHINA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 CHINA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 103 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 104 CHINA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 CHINA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 CHINA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 CHINA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 CHINA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 109 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 110 CHINA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 111 CHINA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 112 CHINA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 113 CHINA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 CHINA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 CHINA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 116 CHINA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 CHINA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 CHINA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 119 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 120 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 121 CHINA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 CHINA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 CHINA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 124 CHINA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 CHINA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 JAPAN IMAGING TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 JAPAN BIOPSY TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 JAPAN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 131 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 132 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 133 JAPAN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 JAPAN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 JAPAN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 136 JAPAN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 137 JAPAN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 139 JAPAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 140 JAPAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 141 JAPAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 142 JAPAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 JAPAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 144 JAPAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 145 JAPAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 JAPAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 JAPAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 148 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 149 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 150 JAPAN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 151 JAPAN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 JAPAN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 JAPAN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 154 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 155 JAPAN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 157 INDIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 158 INDIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 INDIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 160 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 161 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 162 INDIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 INDIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 164 INDIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 165 INDIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 INDIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 168 INDIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 169 INDIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 170 INDIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 171 INDIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 172 INDIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 173 INDIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 174 INDIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 INDIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 176 INDIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 177 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 178 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 179 INDIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 180 INDIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 INDIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 INDIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 183 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 184 INDIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 185 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 SOUTH KOREA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 SOUTH KOREA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 SOUTH KOREA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 189 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 190 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 191 SOUTH KOREA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 192 SOUTH KOREA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 193 SOUTH KOREA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 194 SOUTH KOREA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 SOUTH KOREA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 196 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 198 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 199 SOUTH KOREA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 200 SOUTH KOREA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 SOUTH KOREA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 202 SOUTH KOREA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 203 SOUTH KOREA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 SOUTH KOREA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 205 SOUTH KOREA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 206 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 207 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 208 SOUTH KOREA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 209 SOUTH KOREA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 SOUTH KOREA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 SOUTH KOREA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 212 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 213 SOUTH KOREA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 214 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 215 AUSTRALIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 216 AUSTRALIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 217 AUSTRALIA BIOMAKER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 218 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 219 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 220 AUSTRALIA RENAL CELL CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 221 AUSTRALIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 222 AUSTRALIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 223 AUSTRALIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 AUSTRALIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 226 AUSTRALIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 227 AUSTRALIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 228 AUSTRALIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 229 AUSTRALIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 230 AUSTRALIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 231 AUSTRALIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 232 AUSTRALIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 233 AUSTRALIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 234 AUSTRALIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 235 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 236 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 AUSTRALIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 238 AUSTRALIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 AUSTRALIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 AUSTRALIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 242 AUSTRALIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 243 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 244 TAIWAN IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 245 TAIWAN BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 246 TAIWAN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 247 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 248 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 249 TAIWAN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 250 TAIWAN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 251 TAIWAN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 252 TAIWAN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 253 TAIWAN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 254 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 255 TAIWAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 256 TAIWAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 257 TAIWAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 258 TAIWAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 259 TAIWAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 260 TAIWAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 261 TAIWAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 262 TAIWAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 263 TAIWAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 264 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 265 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 266 TAIWAN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 267 TAIWAN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 TAIWAN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 269 TAIWAN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 270 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 271 TAIWAN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 272 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 273 NEW ZEALAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 274 NEW ZEALAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 275 NEW ZEALAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 276 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 277 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 278 NEW ZEALAND RENAL CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 279 NEW ZEALAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 280 NEW ZEALAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 281 NEW ZEALAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 282 NEW ZEALAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 283 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 284 NEW ZEALAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 285 NEW ZEALAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 286 NEW ZEALAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 287 NEW ZEALAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 288 NEW ZEALAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 289 NEW ZEALAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 290 NEW ZEALAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 291 NEW ZEALAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 292 NEW ZEALAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 293 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 294 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 295 NEW ZEALAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 296 NEW ZEALAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 297 NEW ZEALAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 298 NEW ZEALAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 299 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 300 NEW ZEALAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 301 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 302 INDONESIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 303 INDONESIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 304 INDONESIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 305 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 306 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 307 INDONESIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 308 INDONESIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 309 INDONESIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 310 INDONESIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 311 INDONESIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 312 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 313 INDONESIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 314 INDONESIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 315 INDONESIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 316 INDONESIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 317 INDONESIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 318 INDONESIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 319 INDONESIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 320 INDONESIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 321 INDONESIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 322 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 323 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 324 INDONESIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 325 INDONESIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 326 INDONESIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 327 INDONESIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 328 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 329 INDONESIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 330 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 331 THAILAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 332 THAILAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 333 THAILAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 334 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 335 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 336 THAILAND RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 337 THAILAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 338 THAILAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 339 THAILAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 340 THAILAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 341 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 342 THAILAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 343 THAILAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 344 THAILAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 345 THAILAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 346 THAILAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 347 THAILAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 348 THAILAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 THAILAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 350 THAILAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 351 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 352 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 353 THAILAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 354 THAILAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 355 THAILAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 356 THAILAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 357 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 358 THAILAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 359 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 360 PHILIPPINES IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 361 PHILIPPINES BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 362 PHILIPPINES BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 363 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 364 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 365 PHILIPPINES RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 366 PHILIPPINES CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 367 PHILIPPINES NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 368 PHILIPPINES PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 369 PHILIPPINES CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 370 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 371 PHILIPPINES INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 372 PHILIPPINES INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 373 PHILIPPINES INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 374 PHILIPPINES PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 375 PHILIPPINES PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 376 PHILIPPINES PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 377 PHILIPPINES KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 378 PHILIPPINES KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 379 PHILIPPINES KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 380 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 381 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 382 PHILIPPINES SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 383 PHILIPPINES DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 384 PHILIPPINES PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 385 PHILIPPINES RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 386 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 387 PHILIPPINES KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 388 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 389 MALAYSIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 390 MALAYSIA BIOPSY TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 391 MALAYSIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 392 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 393 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 394 MALAYSIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 395 MALAYSIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 396 MALAYSIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 397 MALAYSIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 398 MALAYSIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 399 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 400 MALAYSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 401 MALAYSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 402 MALAYSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 403 MALAYSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 404 MALAYSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 405 MALAYSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 406 MALAYSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 407 MALAYSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 408 MALAYSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 409 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 410 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 411 MALAYSIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 412 MALAYSIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 413 MALAYSIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 414 MALAYSIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 415 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 416 MALAYSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 417 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 418 VIETNAM IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 419 VIETNAM BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 420 VIETNAM BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 421 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 422 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 423 VIETNAM RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 424 VIETNAM CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 425 VIETNAM NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 426 VIETNAM PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 427 VIETNAM CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 428 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 429 VIETNAM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 430 VIETNAM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 431 VIETNAM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 432 VIETNAM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 433 VIETNAM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 434 VIETNAM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 435 VIETNAM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 436 VIETNAM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 437 VIETNAM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 438 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 439 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 440 VIETNAM SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 441 VIETNAM DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 442 VIETNAM PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 443 VIETNAM RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 444 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 445 VIETNAM KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 446 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 447 SINGAPORE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 448 SINGAPORE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 449 SINGAPORE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 450 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 451 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 452 SINGAPORE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 453 SINGAPORE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 454 SINGAPORE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 455 SINGAPORE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 456 SINGAPORE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 457 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 458 SINGAPORE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 459 SINGAPORE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 460 SINGAPORE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 461 SINGAPORE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 462 SINGAPORE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 463 SINGAPORE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 464 SINGAPORE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 465 SINGAPORE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 466 SINGAPORE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 467 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 468 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 469 SINGAPORE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 470 SINGAPORE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 471 SINGAPORE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 472 SINGAPORE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 473 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 474 SINGAPORE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 475 REST OF ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET
FIGURE 14 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020)
FIGURE 15 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020)
FIGURE 16 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022
FIGURE 17 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 18 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)
FIGURE 19 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE
FIGURE 20 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022
FIGURE 21 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 22 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030)
FIGURE 23 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE
FIGURE 24 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022
FIGURE 25 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 26 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 27 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE
FIGURE 28 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022
FIGURE 29 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 30 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030)
FIGURE 31 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE
FIGURE 32 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022
FIGURE 33 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 34 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 35 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 36 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022
FIGURE 37 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 38 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030)
FIGURE 39 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE
FIGURE 40 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022
FIGURE 41 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)
FIGURE 42 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)
FIGURE 43 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 44 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 45 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 46 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 47 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 49 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 50 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 51 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 52 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 53 ASIA PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
